Key result
SSRI/SNRI use linked to ~36% higher 2-year dementia risk vs psychotherapy in older depressed adults.
Why the study?
Prior studies linking antidepressant use to increased dementia risk compared to no use are subject to confounding by indication. This study aimed to compare dementia risk among older adults with depression initiating first-line antidepressants versus psychotherapy.
Does first-line antidepressant use (SSRI/SNRI) increase the risk of dementia compared to psychotherapy in older adults with depression?
Cohort (n=2,710)
Yes
Does first-line antidepressant use (SSRI/SNRI) increase the risk of dementia compared to psychotherapy in older adults with depression?
Odds Ratio: 1.36 (95% CI 1.06–1.74)
Absolute Event Rate: 16.4% vs 11.8%
In older adults with depression, the use of first-line antidepressants (SSRIs/SNRIs) is associated with a significantly increased risk of incident dementia within 2 years compared to psychotherapy.
SSRI/SNRI use may raise dementia risk versus psychotherapy in depressed older adults; leaves open confounding versus causality, needing prospective confirmation.
BACKGROUND: Prior studies suggested that antidepressant use is associated with an increased risk of dementia compared to no use, which is subject to confounding by indication. We aimed to compare the dementia risk among older adults with depression receiving first-line antidepressants (i.e., SSRI/SNRI) versus psychotherapy, which is also considered the first-line therapy for depression. METHODS: This retrospective cohort study was conducted using the US Medical Expenditure Panel Survey from 2010 to 2019. We included adults aged ≥ 50 years diagnosed with depression who initiated SSRI/SNRI or psychotherapy. We excluded patients with a dementia diagnosis before the first record of SSRI/SNRI use or psychotherapy. The exposure was the patient's receipt of SSRI/SNRI (identified from self-report questionnaires) or psychotherapy (identified from the Outpatient Visits or Office-Based Medical Provider Visits files). The outcome was a new diagnosis of dementia within 2 years (i.e., survey panel period) identified using ICD-9/ICD-10 codes from the Medical Conditions file. Using a multivariable logistic regression model, we reported adjusted odds ratios (aORs) with 95% confidence intervals (CIs). We also conducted subgroup analyses by patient sex, age group, race/ethnicity, severity of depression, combined use of other non-SSRI/SNRI antidepressants, and presence of underlying cognitive impairment. RESULTS: Among 2,710 eligible patients (mean age = 61 ± 8, female = 69%, White = 84%), 89% used SSRIs/SNRIs, and 11% received psychotherapy. The SSRI/SNRI users had a higher crude incidence of dementia than the psychotherapy group (16.4% vs. 11.8%), with an aOR of 1.36 (95% CI = 1.06-1.74). Subgroup analyses yielded similar findings as the main analyses, except no significant association for patients who were aged < 65 years (1.23, 95% CI = 0.93-1.62), male (1.34, 95% CI = 0.95-1.90), Black (0.76, 95% CI = 0.48-1.19), had a higher PHQ-2 (1.39, 95% CI = 0.90-2.15), and had underlying cognitive impairment (1.06, 95% CI = 0.80-1.42). CONCLUSIONS: Our findings suggested that older adults with depression receiving SSRIs/SNRIs were associated with an increased dementia risk compared to those receiving psychotherapy.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) conducted a cohort in Depression (n=2,710). SSRIs/SNRIs vs. Psychotherapy was evaluated on New diagnosis of dementia within 2 years (aOR 1.36, 95% CI 1.06-1.74). Among older adults with depression, SSRI/SNRI use was associated with a 36% increased odds of incident dementia within 2 years compared to receiving psychotherapy (aOR 1.36).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: